Literature DB >> 28642266

T1 Signal Measurements in Pediatric Brain: Findings after Multiple Exposures to Gadobenate Dimeglumine for Imaging of Nonneurologic Disease.

G K Schneider1, J Stroeder2, G Roditi3, C Colosimo4, P Armstrong3, M Martucci4, A Buecker2, P Raczeck2.   

Abstract

BACKGROUND AND
PURPOSE: Signal intensity increases possibly suggestive of gadolinium retention have recently been reported on unenhanced T1-weighted images of the pediatric brain following multiple exposures to gadolinium-based MR contrast agents. Our aim was to determine whether T1 signal changes suggestive of gadolinium deposition occur in the brains of pediatric nonneurologic patients after multiple exposures to gadobenate dimeglumine.
MATERIALS AND METHODS: Thirty-four nonneurologic patients (group 1; 17 males/17 females; mean age, 7.18 years) who received between 5 and 15 injections (mean, 7.8 injections) of 0.05 mmol/kg of gadobenate during a mean of 2.24 years were compared with 24 control patients (group 2; 16 males/8 females; mean age, 8.78 years) who had never received gadolinium-based contrast agents. Exposure to gadobenate was for diagnosis and therapy monitoring. Five blinded readers independently determined the signal intensity at ROIs in the dentate nucleus, globus pallidus, pons, and thalamus on unenhanced T1-weighted spin-echo images from both groups. Unpaired t tests were used to compare signal-intensity values and dentate nucleus-pons and globus pallidus-thalamus signal-intensity ratios between groups 1 and 2.
RESULTS: Mean signal-intensity values in the dentate nucleus, globus pallidus, pons, and thalamus of gadobenate-exposed patients ranged from 366.4 to 389.2, 360.5 to 392.9, 370.5 to 374.9, and 356.9 to 371.0, respectively. Corresponding values in gadolinium-based contrast agent-naïve subjects were not significantly different (P > .05). Similarly, no significant differences were noted by any reader for comparisons of the dentate nucleus-pons signal-intensity ratios. One reader noted a difference in the mean globus pallidus-thalamus signal-intensity ratios (1.06 ± 0.006 versus 1.02 ± 0.009, P = .002), but this reflected nonsignificantly higher T1 signal in the thalamus of control subjects. The number of exposures and the interval between the first and last exposures did not influence signal-intensity values.
CONCLUSIONS: Signal-intensity increases potentially indicative of gadolinium deposition are not seen in pediatric nonneurologic patients after multiple exposures to low-dose gadobenate.
© 2017 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28642266      PMCID: PMC7963691          DOI: 10.3174/ajnr.A5270

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  46 in total

1.  Role of thermodynamic and kinetic parameters in gadolinium chelate stability.

Authors:  Jean-Marc Idée; Marc Port; Caroline Robic; Christelle Medina; Monique Sabatou; Claire Corot
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

2.  High T1 Signal Intensity in Dentate Nucleus after Multiple Injections of Linear Gadolinium Chelates.

Authors:  Carlo Cosimo Quattrocchi; Carlo Augusto Mallio; Yuri Errante; Bruno Beomonte Zobel
Journal:  Radiology       Date:  2015-08       Impact factor: 11.105

3.  Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol.

Authors:  Dragan A Stojanov; Aleksandra Aracki-Trenkic; Slobodan Vojinovic; Daniela Benedeto-Stojanov; Srdjan Ljubisavljevic
Journal:  Eur Radiol       Date:  2015-06-25       Impact factor: 5.315

4.  Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration.

Authors:  Giovanni Morana; Luigi Grazioli; Miles A Kirchin; Maria Pia Bondioni; Niccolò Faccioli; Alessandro Guarise; Günther Schneider
Journal:  Invest Radiol       Date:  2011-04       Impact factor: 6.016

5.  T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T.

Authors:  Yaqi Shen; Frank L Goerner; Christopher Snyder; John N Morelli; Dapeng Hao; Daoyu Hu; Xiaoming Li; Val M Runge
Journal:  Invest Radiol       Date:  2015-05       Impact factor: 6.016

Review 6.  T1 hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition?

Authors:  Nigel Hoggard; Giles H Roditi
Journal:  Br J Radiol       Date:  2016-10-19       Impact factor: 3.039

Review 7.  Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.

Authors:  J T Heverhagen; G A Krombach; E Gizewski
Journal:  Rofo       Date:  2014-01-29

8.  High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material.

Authors:  Tomonori Kanda; Kazunari Ishii; Hiroki Kawaguchi; Kazuhiro Kitajima; Daisuke Takenaka
Journal:  Radiology       Date:  2013-12-07       Impact factor: 11.105

9.  Increased signal intensities in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evidence in children undergoing multiple gadolinium MRI exams.

Authors:  Houchun H Hu; Amber Pokorney; Richard B Towbin; Jeffrey H Miller
Journal:  Pediatr Radiol       Date:  2016-06-09

10.  Signal Change in the Dentate Nucleus on T1-Weighted MR Images After Multiple Administrations of Gadopentetate Dimeglumine Versus Gadobutrol.

Authors:  Yan Cao; Daisy Q Huang; George Shih; Martin R Prince
Journal:  AJR Am J Roentgenol       Date:  2015-12-23       Impact factor: 3.959

View more
  11 in total

Review 1.  Gadolinium-based contrast agents - review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients.

Authors:  Einat Blumfield; David W Swenson; Ramesh S Iyer; A Luana Stanescu
Journal:  Pediatr Radiol       Date:  2019-03-29

Review 2.  Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement.

Authors:  Carlo C Quattrocchi; Joana Ramalho; Aart J van der Molen; Àlex Rovira; Alexander Radbruch
Journal:  Eur Radiol       Date:  2018-11-09       Impact factor: 5.315

Review 3.  A Review of the Current Evidence on Gadolinium Deposition in the Brain.

Authors:  Richard Pullicino; Mark Radon; Shubhabrata Biswas; Maneesh Bhojak; Kumar Das
Journal:  Clin Neuroradiol       Date:  2018-03-09       Impact factor: 3.649

4.  Safety and Diagnostic Efficacy of Gadobenate Dimeglumine in MRI of the Brain and Spine of Neonates and Infants.

Authors:  D S Enterline; K W Martin; H A Parmar; F M Triulzi; C Colosimo
Journal:  AJNR Am J Neuroradiol       Date:  2019-11-14       Impact factor: 3.825

Review 5.  Gadolinium-based contrast agents in children.

Authors:  Michael N Rozenfeld; Daniel J Podberesky
Journal:  Pediatr Radiol       Date:  2018-08-04

6.  The Effects of Gadolinium-Based Contrast Agents on the Cerebellum: from Basic Research to Neurological Practice and from Pregnancy to Adulthood.

Authors:  Winda Ariyani; Miski Aghnia Khairinisa; Gaetano Perrotta; Mario Manto; Noriyuki Koibuchi
Journal:  Cerebellum       Date:  2018-06       Impact factor: 3.847

7.  Changes in signal intensity in the dentate nucleus at unenhanced T1-weighted magnetic resonance imaging depending on class of previously used gadolinium-based contrast agent.

Authors:  Eileen Kasper; Haemi Phaedra Schemuth; Samantha Horry; Sonja Kinner
Journal:  Pediatr Radiol       Date:  2018-02-07

8.  Development of High Signal Intensity within the Globus Pallidus and Dentate Nucleus following Multiple Administrations of Gadobenate Dimeglumine.

Authors:  G M Bolles; M Yazdani; S T Stalcup; S G Creeden; H R Collins; P J Nietert; D R Roberts
Journal:  AJNR Am J Neuroradiol       Date:  2018-01-18       Impact factor: 3.825

9.  Does Age Interfere With Gadolinium Toxicity and Presence in Brain and Bone Tissues?: A Comparative Gadoterate Versus Gadodiamide Study in Juvenile and Adult Rats.

Authors:  Nathalie Fretellier; Agnès Granottier; Marlène Rasschaert; Anne-Laure Grindel; Fannie Baudimont; Philippe Robert; Jean-Marc Idée; Claire Corot
Journal:  Invest Radiol       Date:  2019-02       Impact factor: 6.016

10.  Assessment of gadolinium deposition in the brain tissue of pediatric and adult congenital heart disease patients after contrast enhanced cardiovascular magnetic resonance.

Authors:  Neil Zaki; David Parra; Quinn Wells; Joshua D Chew; Kristen George-Durrett; Sumit Pruthi; Jonathan Soslow
Journal:  J Cardiovasc Magn Reson       Date:  2020-12-03       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.